Skip to main content
. 2017 Oct 16;12(21):1776–1793. doi: 10.1002/cmdc.201700447

Table 4.

CDK‐inhibitory activity of lead compound BAY‐958 and clinical candidate BAY 1143572 in the Merck Millipore KinaseProfilerTM panel.

IC50 [nm] BAY‐958 BAY 1143572
CDK9/CycT1(h) 5 6
CDK1/CycB(h) 690 1100
CDK2/CycE(h) 470 1000
CDK3/CycE(h) 570 890
CDK5/p35(h) 800 1600
CDK6/CycD3(h) 4400 >10 000
CDK7/CycH/MAT1(h) >10 000 >10 000